Fig. 6: CHIR99021 treatment stabilizes CAST in HD models. | Nature Communications

Fig. 6: CHIR99021 treatment stabilizes CAST in HD models.

From: Small-molecule suppression of calpastatin degradation reduces neuropathology in models of Huntington’s disease

Fig. 6: CHIR99021 treatment stabilizes CAST in HD models.The alt text for this image may have been generated using AI.

Total lysates from HdhQ7 and HdhQ111 cells were harvested after the indicated treatments; 3 μM CHIR99021 for 48 h followed by a 2.5 μM lactacystin (Lac) for 12 h or b 250 nM epoxomicin (Epo) for 12 h and subjected to western blotting with the indicated antibodies. Histograms show the relative abundance of CAST (n = 4), calpain I (n = 3), or MCL1 (n = 4). c Calpain enzymatic activity was examined in HdhQ7 and HdhQ111 cells with the indicated treatments: 48 h treatment with CHIR99021 followed by 12 h treatment with Lac (n = 4) or Epo (n = 4). d Total immunoprecipitation (IP) with an anti-CAST antibody followed by western blotting with an anti-ubiquitin antibody. Representative immunoblots and quantification of the relative abundance of ubiquitinated CAST (n = 3). All values are reported as mean ± SEM. Data are representative of at least three independent experiments. Data were compared using one-way ANOVA with Tukey’s post hoc test. Exact p values are shown in the figures.

Back to article page